Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China
Abstract Background Lorlatinib, a third-generation Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (TKI), has demonstrated excellent curative effect in clinical studies to overcome mutations resistant to first- and second-generation ALK-TKIs. It also has improved blood-brain barrier cros...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMC
2025-07-01
|
| Schriftenreihe: | BMC Cancer |
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.1186/s12885-025-14631-w |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|